117 related articles for article (PubMed ID: 21378351)
1. The need for third-line treatment in non-small cell lung cancer: an overview of new options.
Syrigos KN; Saif MW; Karapanagiotou EM; Oikonomopoulos G; De Marinis F
Anticancer Res; 2011 Feb; 31(2):649-59. PubMed ID: 21378351
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
[TBL] [Abstract][Full Text] [Related]
3. Second-line treatment for non-small-cell lung cancer: one size does not fit all.
Caponi S; Vasile E; Ginocchi L; Tibaldi C; Borghi F; D'Incecco A; Lucchesi M; Caparello C; Andreuccetti M; Falcone A
Clin Lung Cancer; 2010 Sep; 11(5):320-7. PubMed ID: 20837457
[TBL] [Abstract][Full Text] [Related]
4. New avenues for second-line treatment of metastatic non-small-cell lung cancer.
Gridelli C; Maione P; Rossi A; Falanga M; Bareschino M; Schettino C; Colantuoni G; Guerriero C; Nicolella D; Rossi E; Ferrara ML; Palazzolo G
Expert Rev Anticancer Ther; 2009 Jan; 9(1):115-24. PubMed ID: 19105711
[TBL] [Abstract][Full Text] [Related]
5. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
[TBL] [Abstract][Full Text] [Related]
7. Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profile.
Vázquez S; Lázaro M; Fírvida JL; Santomé L; Afonso J; Amenedo M; Casal J;
Anticancer Drugs; 2014 Apr; 25(4):368-74. PubMed ID: 24384805
[TBL] [Abstract][Full Text] [Related]
8. Second-line therapeutic options in non-small-cell lung cancer.
Vansteenkiste J
Lung Cancer; 2006 Dec; 54 Suppl 2():S15-8. PubMed ID: 17064813
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
Zhang YF; Chen ZW; Lu S
Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
[TBL] [Abstract][Full Text] [Related]
10. Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions.
Custodio A; de Castro J
Crit Rev Oncol Hematol; 2012 Jun; 82(3):338-60. PubMed ID: 21908201
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N
Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191
[TBL] [Abstract][Full Text] [Related]
12. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
[TBL] [Abstract][Full Text] [Related]
13. Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection.
Ramalingam S; Sandler AB
Oncologist; 2006 Jun; 11(6):655-65. PubMed ID: 16794244
[TBL] [Abstract][Full Text] [Related]
14. Considerations for second-line therapy of non-small cell lung cancer.
Stinchcombe TE; Socinski MA
Oncologist; 2008; 13 Suppl 1():28-36. PubMed ID: 18263772
[TBL] [Abstract][Full Text] [Related]
15. Pemetrexed for the treatment of non-small-cell lung cancer.
Manegold C; Schmid-Bindert G; Pilz LR
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
[TBL] [Abstract][Full Text] [Related]
16. Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.
Doral Stefani S; Giorgio Saggia M; Vicino dos Santos EA
J Med Econ; 2008; 11(3):383-96. PubMed ID: 19450094
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
18. [Pemetrexed salvage chemotherapy for NSCLC: implementation study].
Jungels C; Berghmans T; Meert AP; Lafitte JJ; Scherpereel A; Sculier JP
Rev Mal Respir; 2012 Jan; 29(1):21-7. PubMed ID: 22240216
[TBL] [Abstract][Full Text] [Related]
19. Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies.
de Marinis F; De Santis S; De Petris L
Semin Oncol; 2006 Feb; 33(1 Suppl 1):S17-24. PubMed ID: 16472705
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.
Chang MH; Ahn JS; Lee J; Kim KH; Park YH; Han J; Ahn MJ; Park K
Lung Cancer; 2010 Sep; 69(3):323-9. PubMed ID: 20061047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
